Player size: small large

Continuous Manufacturing for Emergency Preparedness and Rapid Response: Accelerating Widespread Adoption

Jun 4, 2020 1:00pm ‐ Jun 4, 2020 2:30pm

Credits: None available.

Continuous Manufacturing for Emergency Preparedness and Rapid Response: Accelerating Widespread Adoption|The onset of the COVID 19 pandemic has illustrated the importance of the FDA's desired state of a "maximally efficient, agile, flexible pharmaceutical manufacturing sector". Continuous manufacturing has the potential to rapidly respond to changes in demand due to local or global changes. Speakers in this session will discuss how government agencies, pharmacopeial organizations, and industry are working to advance continuous manufacturing and the potential of this technology to respond to the current situation and future challenges. This session will close with an extended panel discussion.

Leader/Speaker(s):

Christine M. Moore, PhD, Executive Director, Quality Systems & Compliance, Organon LLC

Speaker(s):

Stelios C. Tsinontides, Ph.D., FAIChE, Director, Office of Pharmaceutical Manufacturing Assessment (OPMA), OPQ, CDER, FDA
Atul Dubey, PhD, Director, Pharmaceutical Continuous Manufacturing, USP Reference Standards Labs
B. Frank Gupton, PhD, Floyd D. Gotttwald Professor & Chair, Chemical & Life Science Engineering, Virginia Commonwealth University
Anne Fischer, PhD, Programs Manager, Defense Science Office, Defense Advanced Research Projects Agency (DARPA)
Paul Collins, PhD, Senior Director, Small Molecule Design and Development, Eli Lilly and Company

Credits

Credits: None available.

You must be logged in and own this session in order to post comments.